NEW YORK — Cisplatin appears to be superior to cetuximab for patients with locally advanced head and neck cancer regardless of HPV status, according to a presenter at HemOnc Today New York.
However, the optimal approach for patients who truly are ineligible for cisplatin remains controversial, Joshua Bauml, MD, assistant professor of medicine in the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, said during his presentation.
Most patients with head and neck cancer present with locally advanced disease.
Two large studies — RTOG 9501 and

Source link